Symptom-specific TMS Targets for Depression and Anxiety

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

December 28, 2023

Study Completion Date

December 28, 2023

Conditions
DepressionAnxietyMajor Depressive Disorder
Interventions
PROCEDURE

Transcranial magnetic stimulation

Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT04604210 - Symptom-specific TMS Targets for Depression and Anxiety | Biotech Hunter | Biotech Hunter